# Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

> **NCT00731211** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 57 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT00731211
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2011-05
- **Final completion:** 2012-09
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2015-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00731211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00731211, "Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00731211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*